Dr Nurulamin Noor
Dr Nuru Noor is a Clinical Lecturer in Gastroenterology at the Department of Medicine, University of Cambridge. His research is focused on delivery of better outcomes in inflammatory bowel disease through the use of innovations in clinical trials. He was the research fellow for the PROFILE trial – the largest academic, investigator led clinical trial conducted for Crohn’s disease from the UK (and one of the largest in the world). He is now helping to lead the long-term extension study of PROFILE, design Bayesian adaptive trials for less common phenotypes of IBD, and working on downstream translational projects. A key translational component of his work seeks to better understand the biological mechanisms driving outcomes in this condition.
He has received several national and international awards, including prestigious prizes for contributions to clinical trials from: the Royal College of Physicians and the National Clinical Research Network, Academy of Medical Sciences, British Society of Gastroenterology, British Pharmacology Society, European Society of Clinical Investigation, International Consortium of Personalised Medicine, National Institute for Health and Care Research, and European Crohn’s and Colitis Organisation.
Select publications
- Noor NM, Davies N, Tahir W, et al. Anti-TNF treatment from diagnosis is more effective and less costly than conventional ‘step-up’ care for patients with active Crohn’s disease: a cost-effectiveness analysis from the PROFILE trial. Journal of Crohns and Colitis. 2025. PMID 41125135.
- Noor NM, Choodari-Ooskei B, Radford S, Gordon M, Hart AL, Hepburn T, Juszczak E, Lindsay JO, Kennedy NA, Parmar MKB, Jairath V, Moran G. Bringing an adaptive platform trial to Crohn’s disease. Nature Reviews Gastroenterology and Hepatology. 2025. PMID 40045038.
- Noor NM, Estevinho MM, Solitano V, Yuan Y, Kahan B, Jairath V. Applying the estimand framework to IBD clinical trials. Lancet Gastroenterology & Hepatology. 2025. PMID 39914434.
- Noor NM, Sebastian S, Parkes M, Raine T. The need for affordable, pragmatic, investigator-led clinical trials of treatment strategies in inflammatory bowel disease. Lancet Gastroenterology & Hepatology. 2024. PMID 39094586.
- Noor NM, Lee JC, Bond S, et al. A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly-diagnosed Crohn’s disease (PROFILE): a multicentre, open-label randomised controlled trial. Lancet Gastroenterology & Hepatology. 2024. PMID 38402895.
- Noor NM, Raine T. Innovations to improve the efficiency of phase II IBD clinical trials. Nature Reviews Gastroenterology and Hepatology. 2023. PMID 37308780.
- Noor NM, Parkes M, Raine T. Moving towards patient-centred clinical trials in IBD. Nature Reviews Gastroenterology & Hepatology. 2021. PMID 34312526.
- Noor NM, Verstockt B, Parkes M, Lee JC. Personalised Medicine in Crohn’s Disease. Lancet Gastroenterology & Hepatology. 2020;5(1):80-92. PMID 31818474.
Select awards
- Royal College of Physicians and the National Clinical Research Network trainee researcher of the year.
- British Society of Gastroenterology young Gastroenterologist of the year.
- National Institute for Health and Care Research early career researcher impact prize.
- European Crohn’s and Colitis Organisation young clinical researcher of the year.
